Secukinumab

What it is and how it works

Mechanism of Action Secukinumab is a human IgG1 monoclonal antibody that selectively binds to the interleukin-17A (IL-17A) cytokine and inhibits its interaction with the IL-17 receptor. IL-17A is a naturally occurring cytokine that is involved in normal inflammatory and immune responses. Secukinumab inhibits the release of proinflammatory cytokines and chemokines.

Mechanism class: Interleukin-17A Antagonists

Indications

is a human interleukin-17A antagonist indicated for the treatment of: moderate to severe plaque psoriasis (PsO) in adults and pediatric patients 6 years and older who are candidates for systemic therapy or phototherapy. active psoriatic arthritis (PsA) in adults and pediatric patients 2 years of age and older. active ankylosing spondylitis (AS) in adults and pediatric patients 12 years of age and older. active non-radiographic axial spondyloarthritis (nr-axSpA) in adults with objective signs of inflammation. active enthesitis-related arthritis (ERA) in pediatric patients 4 years of age and older. moderate to severe hidradenitis suppurativa (HS) in adults and pediatric patients 12 years of age and older. Plaque Psoriasis COSENTYX ® is indicated for the treatment of moderate to severe plaque psoriasis (PsO) in adults and pediatric patients 6 years and older who are candidates for systemic therapy or phototherapy. Psoriatic Arthritis COSENTYX is indicated for the treatment of active psoriatic arthritis (PsA) in adults and pediatric patients 2 years of age and older.

Dosage and administration (summary)

Prior to COSENTYX initiation, complete all age-appropriate vaccinations, evaluate patients for tuberculosis (TB). See Full Prescribing Information for instructions on preparation and administration of COSENTYX. ( 2.2 , 2.11 , 2.12 ) Administration of Intravenous Formulation: COSENTYX for intravenous use must be diluted prior to administration. Administer as an intravenous infusion after dilution over a period of 30 minutes. Plaque Psoriasis: Subcutaneous Dosage in Adults: Recommended dosage is 300 mg by subcutaneous injection at Weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter. For some patients, a dose of 150 mg may be acceptable.

Contraindications

is contraindicated in patients with a previous serious hypersensitivity reaction to secukinumab or to any of the excipients in COSENTYX. Cases of anaphylaxis and angioedema have been reported during treatment with COSENTYX . Serious hypersensitivity to secukinumab or any excipients in COSENTYX.

Warnings and precautions

Infections : Serious infections have occurred. Exercise caution when considering the use of COSENTYX in patients with a chronic infection or a history of recurrent infection. If a serious infection develops, discontinue COSENTYX until the infection resolves. Hypersensitivity Reactions : If an anaphylactic reaction or other serious allergic reaction occurs, discontinue COSENTYX immediately and initiate appropriate therapy. Tuberculosis (TB) : Prior to initiating treatment with COSENTYX, evaluate for TB. Inflammatory Bowel Disease (IBD) : Cases of IBD were observed in clinical trials.

Pregnancy

Pregnancy Risk Summary Limited available human data with COSENTYX use in pregnant women are insufficient to inform a drug-associated risk of adverse developmental outcomes. In an embryo-fetal development study, no adverse developmental effects were observed in infants born to pregnant monkeys after subcutaneous administration of secukinumab during …

Storage and supply

How Supplied COSENTYX (secukinumab) injection is a clear to opalescent, colorless to slightly yellowish solution available as follows: COSENTYX injection for subcutaneous use Strength Dosage Form Carton Contents NDC 75 mg/0.5 mL COSENTYX prefilled syringe 1 prefilled syringe 0078-1056-97 150 mg/mL COSENTYX prefilled syringe 1 prefilled syringe 0078…

Source: Secukinumab (Cosentyx) — US FDA prescribing information, 2026-08-25, DailyMed. Summarised and shortened; the full label governs. Iranian registration, indications and labelling may differ.